Madopar (Benserazide Hydrochloride, Levodopa)

Levodopa serves as a precursor that crosses the blood‑brain barrier and is converted to dopamine, replenishing depleted central stores. Benserazide inhibits peripheral aromatic L‑amino acid decarboxylase, preventing premature conversion of levodopa outside the brain, which increases the amount reaching the central nervous system and reduces peripheral side effects.

The appropriate dose of Madopar is individualized and set by the prescribing clinician based on the patient’s disease severity, response to therapy, age, renal and hepatic function, and concomitant medications. No standard dosing regimen is provided here; the prescriber will adjust the regimen to achieve optimal symptom control while minimizing adverse effects.

Safety data for Madopar in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare professionals must evaluate each case carefully and discuss potential risks with the patient before initiating therapy.

To order Madopar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Madopar combines levodopa with a peripheral decarboxylase inhibitor, offering higher central availability of dopamine compared with levodopa alone. Compared with dopamine agonists, it provides more potent motor symptom relief but may have a higher incidence of motor complications such as dyskinesia. Choice of therapy depends on disease stage, patient age, and tolerability.

Madopar tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments, which could affect tablet integrity.

Madopar is taken orally, usually with a glass of water. It can be administered with or without food, but a consistent routine helps maintain stable plasma levels. Patients should follow the prescriber’s instructions regarding timing, dose adjustments, and any required separation from other oral medications.

Serious risks include neuroleptic malignant syndrome, severe depression or suicidal ideation, and cardiac arrhythmias. These events are rare but require immediate medical attention. Patients should be educated to recognize early warning signs such as high fever, muscle rigidity, profound mood changes, or irregular heartbeats.

Madopar is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients. It should also be avoided in individuals taking non‑selective monoamine oxidase inhibitors, or those with narrow‑angle glaucoma, malignant melanoma, or severe cardiovascular disease unless specifically advised by a specialist.